JP2017515806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515806A5 JP2017515806A5 JP2016561850A JP2016561850A JP2017515806A5 JP 2017515806 A5 JP2017515806 A5 JP 2017515806A5 JP 2016561850 A JP2016561850 A JP 2016561850A JP 2016561850 A JP2016561850 A JP 2016561850A JP 2017515806 A5 JP2017515806 A5 JP 2017515806A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- poxvirus
- composition according
- oxaliplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/249,713 US9687515B2 (en) | 2007-11-19 | 2014-04-10 | Poxviral oncolytic vectors |
| US14/249,713 | 2014-04-10 | ||
| PCT/EP2015/057654 WO2015155263A1 (en) | 2014-04-10 | 2015-04-09 | Poxviral oncolytic vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515806A JP2017515806A (ja) | 2017-06-15 |
| JP2017515806A5 true JP2017515806A5 (https=) | 2018-04-19 |
| JP6657115B2 JP6657115B2 (ja) | 2020-03-04 |
Family
ID=53051793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561850A Active JP6657115B2 (ja) | 2014-04-10 | 2015-04-09 | ポックスウイルス腫瘍細胞崩壊性ベクター |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3129037B1 (https=) |
| JP (1) | JP6657115B2 (https=) |
| KR (1) | KR102457060B1 (https=) |
| CN (1) | CN106413726B (https=) |
| AU (1) | AU2015243297B2 (https=) |
| CA (1) | CA2943871C (https=) |
| DK (1) | DK3129037T3 (https=) |
| ES (1) | ES2768715T3 (https=) |
| IL (1) | IL247535B (https=) |
| WO (1) | WO2015155263A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018091680A1 (en) * | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| EP3610870A4 (en) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT |
| JP7625521B2 (ja) * | 2018-12-28 | 2025-02-03 | トランスジーン | ｍ２欠陥ポックスウイルス |
| CN110747174A (zh) * | 2019-10-30 | 2020-02-04 | 青岛宁逸生物科技有限公司 | 一种用于肿瘤治疗的重组病毒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| DE69233158T2 (de) * | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| CA2375189C (en) * | 1999-05-28 | 2010-02-09 | The Government Of The United States Of America | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| EP2269619A1 (en) | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
| WO2005007857A1 (en) | 2003-07-21 | 2005-01-27 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
| DK1814907T3 (da) | 2004-11-08 | 2009-05-18 | Transgene Sa | Sæt af dele til designet til implementering af en antitumoral eller antiviral behandling hos et pattedyr |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2009011924A1 (en) * | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| CA2705869C (en) * | 2007-11-19 | 2012-10-30 | Philippe Erbs | Poxviral oncolytic vectors |
| US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| CA2709292A1 (en) * | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
-
2015
- 2015-04-09 WO PCT/EP2015/057654 patent/WO2015155263A1/en not_active Ceased
- 2015-04-09 EP EP15720276.3A patent/EP3129037B1/en active Active
- 2015-04-09 AU AU2015243297A patent/AU2015243297B2/en active Active
- 2015-04-09 JP JP2016561850A patent/JP6657115B2/ja active Active
- 2015-04-09 ES ES15720276T patent/ES2768715T3/es active Active
- 2015-04-09 KR KR1020167030784A patent/KR102457060B1/ko active Active
- 2015-04-09 DK DK15720276.3T patent/DK3129037T3/da active
- 2015-04-09 CN CN201580018763.1A patent/CN106413726B/zh active Active
- 2015-04-09 CA CA2943871A patent/CA2943871C/en active Active
-
2016
- 2016-08-29 IL IL247535A patent/IL247535B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2212423T3 (en) | oncolytic poxvirus vectors | |
| JP2013189456A5 (https=) | ||
| CA3031416C (en) | Recombinant vaccinia virus and use thereof | |
| JP2012067116A5 (https=) | ||
| ES2905478T3 (es) | Virus oncolíticos y moléculas terapéuticas | |
| JP2017523777A5 (https=) | ||
| WO2017037292A1 (en) | Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer | |
| JP2016506413A5 (https=) | ||
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| EP3293201B1 (en) | Combining adenovirus and checkpoint inhibitors for treating cancer | |
| JP2013516454A5 (https=) | ||
| JP2017515806A5 (https=) | ||
| JP2019038796A5 (https=) | ||
| US20240002547A1 (en) | Therapeutic multi-targeting constructs and uses thereof | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| Parrasia et al. | Targeting pancreatic ductal adenocarcinoma (PDAC) | |
| JP2019038797A5 (https=) | ||
| IL272874B1 (en) | [6r]-mthf an efficient folate alternative in 5-fluorouracil based chemotherapy | |
| JP2018100243A5 (https=) | ||
| Shih et al. | Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models | |
| JP2021511344A5 (https=) | ||
| CA2943871C (en) | POXVIRAL ONCOLYTIC VECTORS | |
| WO2020011754A1 (en) | Chimeric vaccinia viruses |